{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:43:06Z","timestamp":1784022186942,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11325-026-03574-6","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:57:10Z","timestamp":1771905430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Benefit-risk comparison of gabapentin enacarbil versus pregabalin for restless legs syndrome: A dose-response model-based network meta-analysis"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5102-5193","authenticated-orcid":false,"given":"Imran H.","family":"Iftikhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad T.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essa","family":"Albisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Dworetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-6167","authenticated-orcid":false,"given":"Ahmed S.","family":"BaHammam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"3","key":"3574_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13783","volume":"32","author":"A Brostrom","year":"2023","unstructured":"Brostrom A, Alimoradi Z, Lind J, Ulander M, Lundin F, Pakpour A (2023) Worldwide estimation of restless legs syndrome: a systematic review and meta-analysis of prevalence in the general adult population. J Sleep Res (3):e13783. https:\/\/doi.org\/10.1111\/jsr.13783","journal-title":"J Sleep Res"},{"key":"3574_CR2","doi-asserted-by":"publisher","unstructured":"Allen RP, Ondo WG, Ball E et al (2011) Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. https:\/\/doi.org\/10.1016\/j.sleep.2011.03.003","DOI":"10.1016\/j.sleep.2011.03.003"},{"key":"3574_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2016.01.017","author":"D Garcia-Borreguero","year":"2016","unstructured":"Garcia-Borreguero D, Silber MH, Winkelman JW et al (2016) Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. https:\/\/doi.org\/10.1016\/j.sleep.2016.01.017","journal-title":"Sleep Med"},{"key":"3574_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nrneurol.2015.122","volume":"8","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Winkelmann J, Inoue Y, Paulus W (2015) Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol 8:434\u2013445. https:\/\/doi.org\/10.1038\/nrneurol.2015.122","journal-title":"Nat Rev Neurol"},{"key":"3574_CR5","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/ene.13449","volume":"12","author":"IH Iftikhar","year":"2017","unstructured":"Iftikhar IH, Alghothani L, Trotti LM (2017) Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol 12:1446\u20131456. https:\/\/doi.org\/10.1111\/ene.13449","journal-title":"Eur J Neurol"},{"key":"3574_CR6","doi-asserted-by":"publisher","unstructured":"Winkelman JW, Berkowski JA, DelRosso LM et al (2025) Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. https:\/\/doi.org\/10.5664\/jcsm.11390","DOI":"10.5664\/jcsm.11390"},{"key":"3574_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.5665\/sleep.1988","volume":"8","author":"RN Aurora","year":"2012","unstructured":"Aurora RN, Kristo DA, Bista SR et al (2012) The treatment of restless legs syndrome and periodic limb movement disorder in adults\u2013an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American academy of sleep medicine clinical practice guideline. Sleep 8:1039\u20131062. https:\/\/doi.org\/10.5665\/sleep.1988","journal-title":"Sleep"},{"key":"3574_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1023\/a:1018951214146","volume":"2","author":"BH Stewart","year":"1993","unstructured":"Stewart BH, Kugler AR, Thompson PR, Bockbrader HN (1993) A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 2:276\u2013281. https:\/\/doi.org\/10.1023\/a:1018951214146","journal-title":"Pharm Res"},{"issue":"suppl 2","key":"3574_CR9","first-page":"S73","volume":"36","author":"M McLean","year":"1995","unstructured":"McLean M (1995) Gabapentin. Epilepsia 36(suppl 2):S73\u2013S86","journal-title":"Epilepsia"},{"key":"3574_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/jpet.104.067934","volume":"1","author":"KC Cundy","year":"2004","unstructured":"Cundy KC, Branch R, Chernov-Rogan T et al (2004) XP13512 [(+\/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel Gabapentin prodrug: I. Design, synthesis, enzymatic conversion to Gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 1:315\u2013323. https:\/\/doi.org\/10.1124\/jpet.104.067934","journal-title":"J Pharmacol Exp Ther"},{"key":"3574_CR11","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.clinthera.2009.07.026","volume":"8","author":"R Lal","year":"2009","unstructured":"Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC (2009) Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 8:1776\u20131786. https:\/\/doi.org\/10.1016\/j.clinthera.2009.07.026","journal-title":"Clin Ther"},{"key":"3574_CR12","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/0091270008322909","volume":"12","author":"KC Cundy","year":"2008","unstructured":"Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM (2008) Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 12:1378\u20131388. https:\/\/doi.org\/10.1177\/0091270008322909","journal-title":"J Clin Pharmacol"},{"key":"3574_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.455003.x","author":"E Ben-Menachem","year":"2004","unstructured":"Ben-Menachem E (2004) Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. https:\/\/doi.org\/10.1111\/j.0013-9580.2004.455003.x","journal-title":"Epilepsia"},{"key":"3574_CR14","unstructured":"Center for Drug Evaluation and Research Approval Package Application number (2025) 022399Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022399Orig1s000TOC.cfm. Accessed August 20"},{"key":"3574_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2165\/11634870-000000000-00000","volume":"9","author":"SA VanMeter","year":"2012","unstructured":"VanMeter SA, Kavanagh ST, Warren S, Barrett RW (2012) Dose response of gabapentin enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies. CNS Drugs 9:773\u2013780. https:\/\/doi.org\/10.2165\/11634870-000000000-00000","journal-title":"CNS Drugs"},{"key":"3574_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0091270012439209","volume":"1","author":"R Lal","year":"2013","unstructured":"Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC (2013) Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol 1:29\u201340. https:\/\/doi.org\/10.1177\/0091270012439209","journal-title":"J Clin Pharmacol"},{"key":"3574_CR17","doi-asserted-by":"publisher","unstructured":"Inoue Y, Uchimura N, Kuroda K, Hirata K, Hattori N (2012) Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog Neuropsychopharmacol Biol Psychiatry. https:\/\/doi.org\/10.1016\/j.pnpbp.2011.10.009","DOI":"10.1016\/j.pnpbp.2011.10.009"},{"key":"3574_CR18","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovic J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"3574_CR19","unstructured":"Pedder H, MBNMAdose Dose-response Model-Based Network Meta-Analysis. R package. DOI: 10.5281\/zenodo.8221452. URL: https:\/\/hugaped.github.io\/MBNMAdose\/. CRAN: https:\/\/cran.r-project.org\/package=MBNMAdose"},{"key":"3574_CR20","doi-asserted-by":"publisher","first-page":"180e6","DOI":"10.15082\/jsnt.37.2_180","volume":"37","author":"K Hirata","year":"2020","unstructured":"Hirata K, Inoue Y, Takeuchi M (2020) Gabapentin enacarbil post-marketing clinical study: a randomized, double-blind, placebo-controlled, parallelgroup study in Japanese patients with restless legs syndrome and post-hoc efficacy evaluation using integrated analysis with a Japanese phase II\/III study. [in Japanese]. Neurol Ther 37:180e6. https:\/\/doi.org\/10.15082\/jsnt.37.2_180","journal-title":"Neurol Ther"},{"key":"3574_CR21","doi-asserted-by":"publisher","unstructured":"Allen R, Chen C, Soaita A et al (2010) A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. https:\/\/doi.org\/10.1016\/j.sleep.2010.03.003","DOI":"10.1016\/j.sleep.2010.03.003"},{"key":"3574_CR22","doi-asserted-by":"publisher","unstructured":"Allen RP, Chen C, Garcia-Borreguero D et al (2014) Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1303646","DOI":"10.1056\/NEJMoa1303646"},{"key":"3574_CR23","doi-asserted-by":"publisher","unstructured":"Bogan RK, Bornemann MA, Kushida CA, Tran PV, Barrett RW, Group XPS (2010) Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. https:\/\/doi.org\/10.4065\/mcp.2009.0700","DOI":"10.4065\/mcp.2009.0700"},{"key":"3574_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2018.11.025","author":"D Garcia-Borreguero","year":"2019","unstructured":"Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V (2019) Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med. https:\/\/doi.org\/10.1016\/j.sleep.2018.11.025","journal-title":"Sleep Med"},{"key":"3574_CR25","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1212\/WNL.0b013e3181e1ce73","volume":"23","author":"D Garcia-Borreguero","year":"2010","unstructured":"Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, Fernandez C (2010) Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 23:1897\u20131904. https:\/\/doi.org\/10.1212\/WNL.0b013e3181e1ce73","journal-title":"Neurology"},{"key":"3574_CR26","doi-asserted-by":"publisher","unstructured":"Garcia-Borreguero D, Patrick J, DuBrava S et al (2014) Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. https:\/\/doi.org\/10.5665\/sleep.3558","DOI":"10.5665\/sleep.3558"},{"key":"3574_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1185\/03007995.2012.746217","volume":"1","author":"Y Inoue","year":"2013","unstructured":"Inoue Y, Hirata K, Uchimura N, Kuroda K, Hattori N, Takeuchi M (2013) Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr Med Res Opin 1:13\u201321. https:\/\/doi.org\/10.1185\/03007995.2012.746217","journal-title":"Curr Med Res Opin"},{"key":"3574_CR28","doi-asserted-by":"publisher","unstructured":"Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW, Group XPS (2009) Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS. Neurology. https:\/\/doi.org\/10.1212\/01.wnl.0000341770.91926.cc","DOI":"10.1212\/01.wnl.0000341770.91926.cc"},{"key":"3574_CR29","doi-asserted-by":"publisher","unstructured":"Kushida CA, Walters AS, Becker P et al (2009) A randomized, double-blind, placebo-controlled, crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. https:\/\/doi.org\/10.1093\/sleep\/32.2.159","DOI":"10.1093\/sleep\/32.2.159"},{"key":"3574_CR30","doi-asserted-by":"publisher","unstructured":"Lal R, Ellenbogen A, Chen D et al (2012) A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. https:\/\/doi.org\/10.1097\/WNF.0b013e318259eac8","DOI":"10.1097\/WNF.0b013e318259eac8"},{"key":"3574_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.5664\/JCSM.1074","volume":"3","author":"DO Lee","year":"2011","unstructured":"Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW, Group XPS (2011) A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 3:282\u2013292. https:\/\/doi.org\/10.5664\/JCSM.1074","journal-title":"J Clin Sleep Med"},{"key":"3574_CR32","doi-asserted-by":"publisher","unstructured":"Walters AS, Ondo WG, Kushida CA et al (2009) Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. https:\/\/doi.org\/10.1097\/WNF.0b013e3181b3ab16","DOI":"10.1097\/WNF.0b013e3181b3ab16"},{"key":"3574_CR33","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/mds.23771","volume":"11","author":"JW Winkelman","year":"2011","unstructured":"Winkelman JW, Bogan RK, Schmidt MH, Hudson JD, DeRossett SE, Hill-Zabala CE (2011) Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 11:2065\u20132072. https:\/\/doi.org\/10.1002\/mds.23771","journal-title":"Mov Disord"},{"key":"3574_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3988\/jcn.2025.0092","volume":"4","author":"JS Sunwoo","year":"2025","unstructured":"Sunwoo JS, Cho YW, Shin WC, Byun JI, Shin JW, Jung KY (2025) Efficacy and safety of pregabalin for restless legs syndrome in Korean adults: a randomized, double-blind, placebo-controlled trial. J Clin Neurol 4:325\u2013331. https:\/\/doi.org\/10.3988\/jcn.2025.0092","journal-title":"J Clin Neurol"},{"key":"3574_CR35","unstructured":"https:\/\/www.fda.gov\/files\/drugs\/published\/Pharmacometric-Approach-To-Define-Narrow-Therapeutic-Index-(NTI)-Drugs---Evaluate-Bioequivalence-(BE)-Criteria-for-NTI-Drugs.pdf"},{"key":"3574_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bcp.12293","volume":"2","author":"A Al Hamid","year":"2014","unstructured":"Al Hamid A, Ghaleb M, Aljadhey H, Aslanpour Z (2014) A systematic review of hospitalization resulting from medicine-related problems in adult patients. Br J Clin Pharmacol 2:202\u2013217. https:\/\/doi.org\/10.1111\/bcp.12293","journal-title":"Br J Clin Pharmacol"},{"key":"3574_CR37","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/bcp.13281","volume":"7","author":"S Dimmitt","year":"2017","unstructured":"Dimmitt S, Stampfer H, Martin JH (2017) When less is more - efficacy with less toxicity at the ED50. Br J Clin Pharmacol 7:1365\u20131368. https:\/\/doi.org\/10.1111\/bcp.13281","journal-title":"Br J Clin Pharmacol"},{"key":"3574_CR38","doi-asserted-by":"publisher","unstructured":"Zhang N, Li Y, Lv Y et al (2019) Quantitative comparison of the efficacies of 5 first-line drugs for primary restless leg syndrome. J Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.1426","DOI":"10.1002\/jcph.1426"}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-026-03574-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11325-026-03574-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-026-03574-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:14:20Z","timestamp":1774462460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11325-026-03574-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3574"],"URL":"https:\/\/doi.org\/10.1007\/s11325-026-03574-6","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"value":"1520-9512","type":"print"},{"value":"1522-1709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No Conflicts of Interest. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"63"}}